Medical News

For Immediate Release

Diana Clarke
6801 San Tomas Dr., #113
Citrus Heights, CA 95621
916 722-7125
dianaclarke2001@yahoo.com

Fundraiser Event for Bonnie Black

San Francisco, CA ? November 17, 2003?To benefit Bonnie Black, a local performer, Liz Clee, will sing at a Fund-Raiser Event, Songs of the Heart, on Friday, December 5, 2003, beginning at 8:00 PM at St. Boniface Theater (next to the church), 133 Golden Gate Avenue, San Francisco, CA. Clee is also the coordinator of the event.

The fee is $ 20.00 per person for an evening of live entertainment. Tickets (cash only) will be sold at the door. The event will be dedicated to Bonnie Black, and the proceeds will go toward the support of her cancer treatment.

Bonnie Black will be 32 on the 30th of November. She is a San Leandro resident, medical assistant, and single parent of a 13-year old son. She was born and raised in San Francisco and attended local schools, including Abraham Lincoln High School. She loves animals and at one time had 15 guinea pigs.

?Bonnie started chemo on the 6th of November and will be receiving treatments every Thursday for three months,? says her mother, Diana Clarke.
Bonnie Black has Hodgkin?s Lymphoma?cancer of the lymph system–and is receiving the chemotherapy regimen, Stanford V, a clinical trial.

List of Entertainers
Vocalist / Liz Clee
Pianist / Dave Austin
Special Guests:
Vocalist / Danny Creed
Actress / Shanna Hoda

About the Performers
Liz Clee: Performed at the Plush Room.
Performed at The Great American Music Hall.
Appeared with the Marin Big Band and Diane Shuur.

Danny Creed: Performed at the Plush Room.
Performed at New York City?s Don?t Tell Mama.

Liz Clee and Danny Creed have performed at several of the Bread and Roses benefit shows.

Shanna Hoda: Played the role of Juliet in Cupertino High School?s production of Romeo and Juliet.
Played the role of Tiny Tim in Easy Street Theater?s production of Scrooge?s Christmas Carol .

Any donation would be appreciated. Please send check or money order payable to Bonnie Black, and address it to Eric Black, P.O. Box 16370, San Francisco, CA 94116.

Or visit http://www.cafeshops.com/coloryourworld to make a purchase. Revenue will be donated to Bonnie.

For more information, send email to dianaclarke2001@yahoo.com.

Read entire article

November 13 2003–Today, new knowledge in pathology drives a development of more targeted drugs. This 500 page report structures and analyzes the new generation of targeted therapeutics for the
treatment of cancer.

In the field of cancer therapeutics, cytotoxic drugs will be replaced with treatments based on a biological approach. Hopefully these new therapies will take over the market not only by increasing the efficacy, but also by significantly decreasing the devastating and troublesome side effects elicted by chemotherapy. Bioseeker along with other analysts believes that this will soon have a substantial impact on the market. Rituxan is one obvious example of this transition.

Novel therapeutic strategies include immunotherapy, vascular targeting, antisens, gene therapy, targeted therapeutics and apototic induction have been studied to reveal mainly industry progress but as well key scientific breakthroughs. Several hundreds of therapeutic candidates are competing in this enviroment and many of them will never succeed, whereas a few will turn out to be the big winners.

This Highlight Report will provide you with an update on the early failure of drugs in anti-angiogenesis such as Avastin, Erbitux, SU5416, Marimastat, Endostatin and Angiostatin. The report will also provide you with an update on the recent advances on vascular targeting, the next approach to inhibit angiogenesis. The progress made in gene therapy where only limited number of companies is in late stage clinical trials is also presented. Updates are also given for the development that occurs in the antisense technology, where the drug Affinitek recently failed to prolong the life of lung cancer patients. However, several big drug companies have partnered with antisense drug developers in the hope that the technology might prove succesful. Furthermore, the report gives an overview on the most recent advancements made by pharmaceutical companies in their choice of therapeutic targets, to induce the apoptotic pathways. A field where a number of antisense related companies play an important role, most notorius the antisense agent Genasense, which targets Bcl-2.

For a complete index of this report click on
http://www.researchandmarkets.com/reports/40093

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

Read entire article

December 5 2003–Prostate cancer is the most common male malignancy in Western countries. Wider use of screening and changes in treatment practice will force companies to adapt their products and marketing goals. These changes will occur over the next five years, but manufacturers must implement new business plans now to capitalize on the effects of stage migration at diagnosis and new treatment approaches.

Scope

Quantitative treatment data from over 440 physicians: 60 from Japan, France, Germany, Italy, Spain and the UK, and 80 from the US

Qualitative feedback on key findings and future trends in the treatment of prostate cancer and the management of disease and treatment side effects

Coverage of the hot topics affecting current treatment patterns, from the impact of IMRT on brachytherapy to the increasing use of bisphosphonates

A strong future focus on key issues, including the increasing use of third generation cytotoxics in HRPC and the implementation of screening in Europe

Report Highlights

AstraZeneca is promoting Casodex monotherapy heavily in non-metastatic disease as an alternative to an LHRH agonist. Approval for Casodex monotherapy has been delayed in some markets, but physicians are already prescribing off-label, especially in patients with dementia, a condition that can be exacerbated by the use of LHRH agonists.

In Japan the volume usage of hormonal drug therapy is far more common as the average age of the patient is well over 70 and so curative treatment is often contraindicated. Datamonitor believes the high volume usage of hormonal therapies makes this an important country in which to market effective, low toxicity drugs.

Clinical trials have shown the lack of activity of estramustine in hormone refractory prostate cancer, but the drug is still commonly used because of the lack of alternatives. Recent trial results of estramustine in combination with Aventis? Taxotere show much greater efficacy and usage of this combination is already significant.

This report is designed to:

Identify hot topics and key issues for practicing prostate cancer specialists ? the questions they really want answered

Predict future trends in the treatment of prostate cancer and how to capitalize on forthcoming changes in treatment practice

Plan product development to fill prostate cancer market niches as defined by practicing physicians

For a complete index of this report click on http://www.researchandmarkets.com/reports/41482

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

Read entire article

April 23, 2004 — The Kidney Cancer Association, in cooperation with the U.S. Food & Drug Adminstration Office of Special Health Issues (http://www.fda.gov/oashi/home.html), with grant assistance from Genentech (www.gene.com), has created a simple web-based search tool intended to help patients locate an appropriate clinical trial using the National Library of Medicine clinical trials database and the NexProfiler Treatment Option Tool for Kidney Cancer. To access this tool point your web browser to http://www.kidneycancerhelp.com for more information.

Approximately 200,000 people in the United States are currently living with kidney cancer, a disease that claims nearly 12,000 lives each year. The Kidney Cancer Association serves constituents in the U.S. and 90 other countries from offices located in suburban Chicago.

Read entire article

January 3 2004–We specialize in surgical dermatology, including skin cancer detection and treatment. We offer the latest techniques in dermatologic cosmetic surgery, including Mohs micrographic surgery, hair transplantation, scar correction, laser hair removal, Thermacool (Thermage), fat injection (microlipoinjection or fat transfer), liposuction, weekend facelift, and eyelid lift (blepharoplasty). We treat a variety of dermatologic conditions, including alopecia, acne, rosacea, warts, moles, skin cancer, melanoma, squamous cell carcinoma, basal cell carcinoma.

Read entire article

Myrtle Beach, SC April 7, 2004 -? A new web site for Carolina Regional Cancer Center (CRCC), www.CRCCmd.com, has been designed to offer information on a number of cancer types, symptoms and advanced cancer treatment options. The medical facts provided on the web site are communicated in a clear, concise way to help the general public learn more about how to identify and successfully treat several types of cancer.

“We?ve worked to develop a web site that not only delivers information about CRCC?s capabilities, but also serves as an educational tool for people seeking more in-depth information about various types of cancer and the treatment options available to them,” said Dr. Steve Bass, CRCC?s president and clinical director. “When people hear the word ?cancer,? their first reaction is fear, and knowledge is the greatest weapon against fear. So, we?ve designed our web site to, hopefully, ease some of the fear of cancer by providing knowledge about what several cancers involve and how they can be successfully be treated.”

The CRCC web site has already been praised for both its design and clarity by professional communicators. It was recently given a Silver award at the 20th Annual Healthcare Advertising Awards held earlier this May. The awards are sponsored by the well-respected national trade journal, Healthcare Marketing Report. In early 2003, it was honored with a Silver ADDY award at the 2003 American Advertising Federation?s ADDY Awards sponsored by the AAF?s Coastal Advertising and Marketing Professionals chapter.

Located in the heart of Myrtle Beach, S.C., CRCC offers one of the most advanced cancer treatments available, Intensity Modulated Radiation Therapy (IMRT). Explained in detail on the CRCC Web site, IMRT offers hope, where previously there often was none. Recognized by radiation oncologists as the greatest technological advancement in radiation therapy in the past 30 years, IMRT is an extremely precise and complex form of radiation therapy that delivers high doses of radiation to cancer cells while minimizing the exposure of nearby healthy tissue.

The CRCC Web site was designed and is maintained by LHWH Advertising & Public Relations of Myrtle Beach.

About Carolina Regional Cancer Center
Carolina Regional Cancer Center is a health care facility that provides comprehensive radiotherapeutic services and treatments. The state-of-the-art center is located at 4708 Oleander Drive, Myrtle Beach, SC.

CRCC has three board-certified radiation oncologists, medical physicists, dosimetrists, and treatment planning and treatment delivery specialists among its 30 full-time staff members.

R. Steven Bass, M.D. is the Clinical Director of CRCC. Dr. Bass has special interest in prostate and gastrointestinal tract cancers. He completed residency training at Vanderbilt University Medical Center and the Medical University of South Carolina (MUSC). He graduated medical school from Vanderbilt University School of Medicine in Nashville, TN, after graduating with highest honors from the University of Florida with degrees in biochemistry and microbiology and cell science.

Terence Moore, M.D., F.A.C.R. (Fellow of the American College of Radiology), completed his residency in radiation technology at Duke University Medical Center and received training in surgical pathology at Wilford Hall U.S. Air Force Medical Center. He has written 17 peer-reviewed medical journals and served as principal investigator on numerous leading-edge studies on optimum radiation doses, reducing toxicity and increasing effectiveness of radiation therapy. A past assistant professor of radiation oncology at MUSC, he has a special interest in pediatric malignancies and breast cancer cases.

Todd Williams, M.D., has done extensive research in radiation therapy and has received numerous grants to fund his work. He completed his residency in radiation oncology at MUSC, and remains an assistant professor of radiation oncology at the school. An invited reviewer for many peer-reviewed journals, Dr. Williams has lectured at events sponsored by MUSC and other organizations. He has published nine articles and five abstracts or manuscripts in peer-reviewed journals and has special interest in lung, head, neck and esophageal cancers.

More information about CRCC and its progressive treatment capabilities is available online at www.CRCCmd.com or by calling 843-449-9415.

Read entire article

December 4 2003–This report explores the products that will shape the future of the cancer market, and analyses the most attractive areas of exploration and strategies for development.

The global cancer market is predicted to be worth around $20 billion in 2003, and is expected to increase to over $45 billion by 2011. Over the next decade, advances in the pharmacotherapy of cancer will come not only from improvements in the traditional classes of therapies, but also from introduction of innovative therapies that display improved efficacy and toxicity through a targeted approach.

The traditional treatment classes including cytotoxic and hormonal therapies will continue to form the backbone of standard cancer therapy, and so should continue to achieve strong sales in the short-term. The cancer market will see continued strong growth of the innovatives classes of therapies, which includes immunostimulators, tumor targeted therapies and growth inhibitors. Pharmaceutical companies should invest in the development or in-licensing of innovative cancer treatments to maintain market share. The key to the success of an innovative therapy is synergy with traditional therapies.

Scope:

- Patient potential of the ten major tumor types, including key trends in their epidemiology and reviews of their current treatment methods
- Data for the following cancers: breast, prostate, lung, colorectal, ovarian, brain, pancreatic, head and neck, leukemia and malignant melanoma
- Company oncology pipeline analysis of Aventis, Roche, and Bristol-Myers Squibb
Analysis of the phase III drugs, including clinical trial data and descriptions of their market potential, with sales forecasts to 2011 for key drugs

Report Highlights:

- This report predicts that the 10 major tumor types in this report will be responsible for the deaths of over 1.25 million people in 2003 within the seven major markets. The size of the cancer problem is reflected by the size of the global cancer market, which is predicted to be worth around $20 billion in 2003.
- The traditional treatment classes including cytotoxic and hormonal therapies will continue to form the backbone of standard cancer therapy, and hence should continue to achieve strong sales in the short-term.
- The cancer market will see continued strong growth of the innovatives classes of therapies. Pharmaceutical companies should invest in the development or in-licensing of innovative cancer treatments to maintain market share. The key to the success of an innovative therapy is synergy with traditional therapies.

This report is designed to:

- Assess competitive threat from novel compounds entering the cancer market
- Characterize saturated and under-served markets in cancer
- Find potential out-licensing and co-marketing partners in the cancer market

For a complete index of this report click on http://www.researchandmarkets.com/reports/40250

About Research and Markets Ltd.
Research and Markets Ltd. are Europe’s largest resource for market research. R&M distribute thousands of major research publications from the world’s leading publishers, consultants and market analysts. R&M provide you with the latest forecasts on international and regional markets, key industries, the top companies, new products and the latest market trends.

For additional information on ResearchandMarkets.com, their range of reports or their value-added services, visit their web site at http://www.researchandmarkets.com or mailto:press@researchandmarkets.com

Read entire article